// App-Quantinova.ai

3532 : High levels of cell-free DNA (cfDNA) at baseline (BL) and increase of at least one mutation at day 14 (D14) as independent prognostic biomarkers for patients (pts) with advanced colorectal cancer (aCRC) under regorafenib.

Researchers

Presenter

  • Pashalina Kehagias

Principal Investigators

  • Lieveke Ameye

  • Hakim El Housni

  • Amelie Deleporte

  • Karen Paula Geboes

  • Thierry Delaunoit

  • Marc Peeters

  • Gauthier Demolin

  • Lionel A. D'Hondt

  • Jozef Janssens

  • Javier Carrasco

  • Stephane Holbrechts

  • Jean-Charles Goeminne

  • Philippe Vergauwe

  • Jean-Luc Van Laethem

  • Ghanem Ghanem

  • Marianne Paesmans

  • Patrick Flamen

  • Alain Hendlisz

Medical Centers

  • Gastro-Oncology Translational Laboratory, Institut Jules Bordet - Universite Libre de Bruxelles (ULB), Brussels, Belgium

  • Data Centre, Institut Jules Bordet - Universite Libre de Bruxelles (ULB), Brussels, Belgium

  • Department of medical Genetics, Hopital Erasme-ULB, Bruxelles, Belgium

  • Institute Jules Bordet, Brussels, Belgium

  • UZ Ghent, Ghent, Belgium

  • 5Oncology department, Hopital de Jolimont, La Louviere, Haine-Saint-Paul, Belgium

  • Department of oncology, Antwerp University Hospital, Edegem, Belgium

  • St. Joseph's Community Health Centre, Liege, Belgium

  • Cliniques Universitaires Saint-Luc, Namur, Belgium

  • AZ Turnhout, Turnhout, Belgium

  • Grand Hopital De Charleroi, Charleroi, Belgium

  • 11Service of Medical Oncology, Centre Hospitalier Universitaire Ambroise Pare, Mons, Belgium

  • Service of Medical Oncology, Cliniques et Maternite Ste Elizabeth, Namur, Belgium

  • AZ Groeninge, Kortrijk, Belgium

  • Erasme Hospital, Bruxelles, Belgium

  • Institut J. Bordet, Laboratory of Oncology and Experimental Surgery (L.O.C.E.), Bruxelles, Belgium

  • Data Centre, Institut Jules Bordet - Universite Libre de Bruxelles (ULB), Brussels, Belgium

  • Institut Jules Bordet, Universite libre de Bruxelles, Brussels, Belgium

Locations

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating DNA

  • Plasma cell-free DNA

Drug/Treatment

  • Regorafenib

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • NCT01929616

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved